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Introduction
Asthma is a chronic, inflammatory disease, which is
characterized by reversible bronchoconstriction asso-
ciated with characteristic signs and symptoms [1,2].
Histopathological examination of bronchial tissue
from asthmatic patients reveals destruction of airway
epithelium and profound infiltrations of inflammatory
cells including T cells, eosinophils, basophils and
monocytes [1,2].  Even in mild, newly diagnosed asth-
ma patients some signs of irreversible bronchial wall
remodeling can be unequivocally demonstrated (3).
Those irreversible changes in the airway wall consist
of increased deposition of extracellular matrix (ECM)
proteins, hyperplasia and hypertrophy of smooth mus-
cle cells, mucous cell metaplasia and increased num-
ber of blood vessels [2]. Progression of these structur-
al changes is associated with increased bronchial
hyperreactivity which clinically can be demonstrated
by an exaggerated response to nonspecific bron-
choconstrictive stimuli such as histamine or meta-
choline [4,5].   
Urokinase-type plasminogen activator (uPA) and
plasminogen activator inhibitor-1 (PAI-1)  play an
important role in the regulation of inflammatory
response and tissue remodeling [6,7].  An important
role of PAI-1 in the regulation of tissue remodeling in
asthma was demonstrated in an OVA-induced  murine
asthma model [8]. Airways of OVA-sensitized and
challenged PAI-1-/- mice were characterized by
reduced collagen and fibrin deposition and increased
matrix metalloproteinase-9 (MMP-9) activity in com-
parison with those of wild type mice.  The plasmino-
gen activator system (PAS) plays an important role in
regulating ECM proteolysis, both directly through
plasmin formation and indirectly through plasmin-
mediated activation of matrix metalloproteinases
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(MMPs) [7]. Plasminogen activator inhibitor-1, the
principal inhibitor of PAS in the alveolar space, has
been recently involved in the pathogenesis of asthma,
by inhibition of both fibrinolysis and the MMP system
[9]. Plasminogen activator inhibitor-1, indeed, pro-
motes ECM deposition in the airways of a murine
model of chronic asthma [8] and its expression is
increased in lung mast cells from asthmatic patients
[10].  The importance of uPA in the regulation of Th-2
type immune response has been recently demonstrated
using uPA deficient mice (uPA-/-).  Those mice have a
profound immune defect in response to an antigen elic-
iting Th-2-type immune response [11].  Primed and
subsequently challenged with schistosomal egg anti-
gen uPA -/- mice fail to generate IgE response and do
not produce high level of interleukin (IL) -4, IL-5 and
IL-13 [11].  Moreover, the number of inflammatory
cells, including eosinophils and T lymphocytes, infil-
trating pulmonary granulomas is significantly reduced
indicating a failure of recruitment of those cells to the
sites of Th-2 type inflammatory response [11].     
Also in humans several studies demonstrated asso-
ciation of fibrynolytic system with asthma and
bronchial hyperresponsiveness [12-17].
It was therefore of interest to evaluate the levels of
locally produced uPA and PAI-1 in the airways of
house dust mite allergic asthmatics (HDM-AAs) in
relation to functional lung parameters and selected
indices of airway inflammation.       
Materials and methods
Study participants. The study was performed on 19 HDM-AAs
and on 8 nonatopic healthy controls (HCs).  The allergic asthmatic
patients had recent episodes of dyspnea, cough and wheezing upon
dust exposure and had positive skin prick test results with house
dust mite allergens, significant bronchoconstrictive response to
inhaled histamine and positive bronchial allergen challenge. All
patients who had received allergen immunotherapy or any anti-
asthma medication, (with the exception of short-acting beta-ago-
nists used as needed) before the initial visit were not included in
the study.  The short acting beta agonists were withdrawn at least
2 days before the study. Other exclusion criteria included respira-
tory tract infection within 3 months before the study, smoking, or
any systemic disease.  
Skin prick tests. All participants were skin tested using prick
methodology with a screening panel of aeroallergens (Aller-
gopharma, Reinbek, Germany) as described earlier [18].  
Bronchial challenge. Histamine bronchial challenge was per-
formed according to the method previously described elsewhere
[18]. Briefly, all patients inhaled doubling concentrations of hista-
mine starting from a concentration of 0.62 mg/ml. Aerosol was
generated using a DeVilbis #646 nebulizer attached to a Rosenthal
- French dosimeter. All subjects performed five inspiratory - capac-
ity breaths of given histamine concentration. Forced expiratory
manoeuvres were performed 90 seconds after each fifth inhalation.
The procedure was continued until either at least 20% fall of FEV1
or histamine concentration 32 mg/ml was reached. Bronchial reac-
tivity to histamine is expressed as histamine concentration causing
20% fall of FEV1 (PC20). 
Bronchial provocation test with aqueous Dp extracts (Aller-
gopharma, Germany) was performed according to the method pre-
viously described elsewhere [18]. In brief, increasing doses of
allergen (0.8, 4, 20, 100, 500 and 2000 SBE) were administered
using a De Vilbis #646 nebulizer attached to a Rosenthal-French
dosimeter. Forced expiratory manoeuvres were performed 15 min-
utes after inhalation of each dose of the allergen extract.  Allergen
inhalations were continued until either at least 20% fall of FEV1 or
a cumulative dose 5000 SBE was reached.  Then FEV1 was meas-
ured every 15 minutes during the first hour, every 60 minutes dur-
ing the next 11 hours and after 24 hours.  Bronchial reactivity to
Dp is expressed as Dp dose causing 20% fall of FEV1 (PD20). 
Bronchial challenge with histamine or Dp allergen extract were
performed only in HDM-AAs.   
Exhaled nitric oxide measurements. Concentration of nitric
oxide (NO) in the expired air was evaluated "on-line" using a
chemiluminescence analyzer NOATM 280i (Sievers, USA). The
measurements were performed according to ATS recommendations
as described before [19].   Briefly, each patient exhaled over a 30 s
period against the fixed expiratory resistance of 16 cm H2O, which
resulted in a constant flow of 50 mL/s. Both NO concentration and
flow rate were displayed on the screen. A plateau of NO concen-
tration in the exhaled air at the selected exhalation rate was auto-
matically selected by the computer software according to the ATS
recommendations. The NO measurements were repeated 3 times
and the mean value was used for analysis. 
Sputum induction Sputum was induced according to the method
originally described by Popov et al. [20] which we presented in
details before [21]. Briefly, after premedication with 200 mcg of
inhaled salbutamol patients inhaled hypertonic saline solution (3 to
5% NaCl).  The collected sputum volume was measured, mixed
with an equal volume of 0.1% DTT (dithiotreitol) and than rocked
at room temperature for 15 minutes.  The samples were subse-
quently filtered through 0.42-μm Millipore filter and centrifuged at
1500 g for 10 minutes. The supernatants were immediately aliquot-
ed and frozen at -70°C until further analysis.  The pellets were
resuspended in phosphate-buffered saline and total number of non-
squamous cells was assessed using Fuchs Rosenthal chamber.    
Biochemical and immunologic assays. Concentration of PAI-1
and uPA antigen in the supernatants was evaluated using enzyme-
linked immunosorbent assays (Asserachrom, Diagnostica Stago,
USA) according to the manufacturer's instruction as described
before [22]. All samples were run in duplicates.  
Ethical issues. The study was approved by the local Ethics Com-
mittee (R-I-003/188/2005).  All participants provided written
informed consent.      
Statistical analysis. Continuous variables were compared using
the Wilcoxon test.  Multiple regression analysis was used to deter-
mine relationship between quantitative parameters. Data for con-
tinuous variables were expressed as median with 95% confidence
intervals (95%CI). All computations were carried out using the
Statistica software. 
Results
There was no difference in gender distribution and age
between HDM-AAs and HC (Table 1).  Patients with
asthma were characterized by significantly lower lung
function parameters and significantly elevated eNO
(Table 1).  In HDM-AAs the median sputum concen-
trations of uPA (128 pg/ml; 95% CI 99 to 183 pg/ml)
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and PAI-1 (4063 pg/ml; 95% CI 3319 to 4784 pg/ml)
were significantly greater than in HCs (17 pg/ml; 95%
CI 12 to 32 pg/ml; p<0.001 and 626 pg/ml; 95% CI
357 to 961 pg/ml; p<0.001, for uPA and PAI-1 respec-
tively) (Table 1). Analysis of functional and immuno-
logic parameters revealed that sputum PAI-1 concen-
tration correlated with baseline FEV1 (r=-0,718;
p=0.0005) and with bronchial reactivity expressed as
logPC20 (r=-0.824; p<0.0001) (Fig. 1). On the contrary
sputum concentration of uPA did not correlate with
lung function test results but was positively correlated
with the number of inflammatory (nonsquamous) cells
in induced sputum (r=0.781; p=0.0001) and with
logeNO (r=0.486; p=0.035). No correlation of sputum
PAI-1 concentration with the number of inflammatory
cells or with eNO was demonstrated.    
Discussion
Our study demonstrates elevated levels of uPA and
PAI-1 in the airways of asthmatic patients suggesting
increased local activation of the PAS in vivo.  This is
consistent with previous studies performed in humans
and in animals [6-17].  However, activation of the PAS
is not associated exclusively with asthma but its acti-
vation could also be demonstrated in other inflamma-
tory lung diseases such as chronic obstructive pul-
monary diseases or cystic fibrosis [23].  The intriguing
finding in this study is association of uPA and PAI-1
with different aspects of asthmatic phenotype.  Con-
centration of uPA in sputum correlated with indices of
airway inflammation, such as sputum cell number or
exhaled nitric oxide concentration, while sputum PAI-
1 concentration was linked with indices of airway
remodeling such as baseline FEV1 or PC20.  Our find-
ings in asthmatic patients are supported by results of
several studies in which PAI-1-/- or uPA-/- mice were
evaluated in different experimental models.  In a
chronic asthma model, PAI-1-/- mice were protected
from increased airway remodeling in response to aller-
gen challenge [8]. Chronic exposure to ovalbumin
resulted in significantly less collagen and fibrin depo-
sition in the airways of PAI-1-/- mice when compared
with wild type mice [8].  Interestingly, however, there
was no significant difference between the number of
inflammatory cells infiltrating airway tissues when
PAI-1-/- mice were compared with wild type mice.
Similar results were obtained in a model of bleomycin-
induced lung fibrosis [24].  No significant change in
the inflammatory cell content could be demonstrated
in bleomycin-challenged wild type and PAI-1-/- mice,
however in the latter animals significant reduction of
lung fibrosis was seen [24].  Those experiments indi-
cate that endogenous PAI-1 exerted little effect on cell
influx to the sites of tissue injury and inflammation but
significantly affects lung remodeling.  
We have been already able to demonstrate that in
asthmatic patients plasma PAI-1 concentration corre-
lates with baseline FEV1 and bronchial response to
histamine, but it does not correlate with peripheral
blood eosinophilia or response to allergen challenge
[15,22].  Moreover, in asthmatic patients the -675 4G
allele of PAI-1 gene, which is a major genetic determi-
nant of increased PAI-1 synthesis, is associated with
lower baseline lung function and greater bronchial
reactivity to histamine, suggesting that propensity for
increased PAI-1 production is linked with bronchial
remodeling [15].  Furthermore, exposure to an aller-
gen, which leads to increased non-specific bronchial
reactivity, induces PAI-1 synthesis [22].  However, no
direct correlation between the increase in plasma PAI-
1 concentration and the provocative dose of an aller-
gen could be demonstrated, indicating that plasma
PAI-1 levels are not directly affected by allergen expo-
sure.  It seems, that the relation between the intensity
of the airway inflammation and PAI-1 synthesis is
complex.  This assumption is supported by our current
findings which show no correlation between sputum
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Table 1. Patients characteristics. 
PAI-1 level and indices of airway inflammation in
allergic asthmatic patients. The indices of airway
inflammation, however, correlated with sputum uPA
concentration suggesting more direct association.  In a
model of Th-2 type immune response, strong effect of
uPA on cell migration has been demonstrated [11,25]
The effect has been demonstrated both in vitro using
eosinophil adhesion assay and in vivo utilizing uPA-/-
mice [11,25].  In comparison with wild type animals,
in uPA-/- mice administration of a schistosomal egg
antigen, which evokes Th-2 type immune response,
resulted in significantly reduced influx of inflammato-
ry cells to the sites of antigen challenge [11].  One of
the possible mechanism responsible for the reduced
influx of eosinophils and T cells to the inflammatory
tissues is decreased adhesion and migration of those
cells in response to chemoattractants [25].  In fact in
vitro studies demonstrated that, exogenous uPA
enhanced eosinophil adhesion to ICAM-1 or VCAM-1
even in the absence of any other agonists [25].  More-
over, this effect was also observed in those cells which
migrate to the airways in response to allergen chal-
lenge [25]. This phenomenon was dependent on uPA
interaction with uPAR, but was independent of uPA
fibrynolytic activity [25].     
In summary, our study indicates that PAS is acti-
vated in the airways of asthmatic subjects.  Inhibitory
effect of PAI-1 is predominantly associated with tissue
remodeling, while uPA is linked with intensity of air-
way inflammation.  Further studies are necessary to
elucidate the exact mechanisms responsible for the
effect of PAS on development of asthma.     
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Fig. 1. Correlations between sputum uPA or PAI-1 concentration and selected parameters of lung function or airway inflammation indices
in HDM-AAs (a to h). FEV1 - forced expiratory volume exhaled during the first second.  PC20 - provocative concentration of histamine
which caused 20% fall of FEV1. (a,b,c,d, - page XX, e,f,g,h - page XX).
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